ARCHIVES

Unwanted Distinction: MSKCC Bars Zaltrap From Formulary, Triggering Debate Over Drug Pricing

This article is from The Cancer Letter archive.

Vol. 38 No. 41 | November 1, 2012

Download PDF Visit The Full Archive

Related Articles

RFA On Hepatitis B Virus, Liver Cancer

April 15, 1983

Risk Assessment Key In Long-Term Treatment

August 29, 2008

NLMs Grateful MED Aids Data Searches

March 21, 1986

Also in this 8-page issue: NCI, FDA open Web site for adverse event reporting.

April 16, 2004

NCI Plans $38 Million For New Research In Tobacco Control Over Next Two Years

October 16, 1998

Avastin Vote Puts Focus On FDA Criteria In First-Line Metastatic Breast Cancer: Is PFS Good Enough?

December 14, 2007